Cardiovascular risks in patients with Subclinical hypothyroidism
- Publisher's listprice EUR 35.90
-
14 889 Ft (14 180 Ft + 5% VAT)
The price is estimated because at the time of ordering we do not know what conversion rates will apply to HUF / product currency when the book arrives. In case HUF is weaker, the price increases slightly, in case HUF is stronger, the price goes lower slightly.
- Discount 5% (cc. 744 Ft off)
- Discounted price 14 145 Ft (13 471 Ft + 5% VAT)
Subcribe now and take benefit of a favourable price.
Subscribe
14 889 Ft
Availability
printed on demand
Why don't you give exact delivery time?
Delivery time is estimated on our previous experiences. We give estimations only, because we order from outside Hungary, and the delivery time mainly depends on how quickly the publisher supplies the book. Faster or slower deliveries both happen, but we do our best to supply as quickly as possible.
Product details:
- Publisher LAP Lambert Academic Publishing
- Date of Publication 1 January 2016
- ISBN 9783659922213
- Binding Paperback
- No. of pages80 pages
- Size 220x150 mm
- Language English 0
Categories
Long description:
Subclinical Hypothyroidism (SCH) is an asymptomatic condition, diagnosed when peripheral thyroid hormone level are with in their normal laboratory reference range but serum thyroid stimulating hormone (TSH) levels are mildly elevated. It is more common in women than men, and its prevalence increases with age. Of patients with SCH, 80% have a serum TSH of less than 10 mIU/L. The most important implication of SCH is high likelihood of progression to clinical hypothyroidism and then to cardiovascular diseases. It has been associated with atherosclerotic cardiovascular disease even in the absence of hypercholesterolemia. The decision to treat SCH patients with Levothyroxine for restoring euthyroidism and improving cardiovascular risk should depend on the presence of risk factors, rather than on a TSH threshold. This study aims at determining the significance of early biochemical markers as effective tool for the detection of early cardiovascular risk in subclinical hypothyroid patients.
More
From Ally to All-In: The Five Stages of Moving Beyond Privilege and Becoming a More Inclusive Leader
Protocols in Human Molecular Genetics
39 919 HUF
36 725 HUF
